NorthStrive Biosciences expands AI drug discovery with Yuva Biosciences
A six-month expansion program with Yuva Biosciences will narrow four validated AI-discovered compounds toward a nominated lead and designated backup. An amendment strengthens the exclusive cardiac disease and obesity field of use.
Building on positive Phase III results from the parties' AI-driven drug discovery program, the six-month Expansion Program will narrow the four validated compounds toward a nominated lead and designated backup.The Amendment also strengthens the exclusive Cardiac Disease and Obesity field of use and…